Research programme: oncolytic virus therapies - Cell Genesys/Genetic Therapy

Drug Profile

Research programme: oncolytic virus therapies - Cell Genesys/Genetic Therapy

Alternative Names: CG4030; CG5757

Latest Information Update: 01 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell Genesys; Genetic Therapy
  • Developer Cell Genesys
  • Class Oncolytic viruses
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Jun 2009 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 07 Mar 2007 Preclinical development of GC 5757 is ongoing for cancer
  • 22 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top